CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 87.5% in December

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 6,000 shares, a growth of 87.5% from the December 15th total of 3,200 shares. Based on an average daily volume of 14,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company’s shares are sold short.

CollPlant Biotechnologies Price Performance

Shares of NASDAQ:CLGN traded down $0.09 during mid-day trading on Tuesday, reaching $3.84. 1,354 shares of the company were exchanged, compared to its average volume of 6,282. The firm has a market cap of $43.99 million, a price-to-earnings ratio of -2.49 and a beta of 0.63. CollPlant Biotechnologies has a 1 year low of $3.24 and a 1 year high of $6.75. The firm’s 50-day simple moving average is $3.98 and its 200 day simple moving average is $4.47.

Analyst Upgrades and Downgrades

CLGN has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a research report on Wednesday, November 27th.

Hedge Funds Weigh In On CollPlant Biotechnologies

A hedge fund recently bought a new stake in CollPlant Biotechnologies stock. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned approximately 0.21% of CollPlant Biotechnologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.